Publication:
Prevalence of cancer in membranous nephropathy: A systematic review and meta-analysis of observational studies

dc.contributor.authorNapat Leeaphornen_US
dc.contributor.authorPogsathorn Kue-A-Paien_US
dc.contributor.authorNatanong Thamcharoenen_US
dc.contributor.authorPatompong Ungpraserten_US
dc.contributor.authorMichael B. Stokesen_US
dc.contributor.authorEric L. Knighten_US
dc.contributor.otherColumbia University in the City of New Yorken_US
dc.contributor.otherColumbia University, College of Physicians and Surgeonsen_US
dc.contributor.otherMahidol Universityen_US
dc.date.accessioned2018-11-09T02:55:14Z
dc.date.available2018-11-09T02:55:14Z
dc.date.issued2014-01-01en_US
dc.description.abstractBackground: The association between membranous nephropathy (MN) and cancer has been well documented. However, the true prevalence and characteristics of cancer associated with MN have not been well described. Methods: A systematic review and meta-analysis of cohort studies was conducted to summarize the prevalence of cancer-associated MN as well as patient characteristics and types of cancer in this population. We used a random-effects meta-analysis model to estimate the prevalence of cancer. Results: We included 6 studies (n = 785). The estimated prevalence of cancer was 10.0% (95% CI, 6.1-14.6). The mean age of MN patients with cancer was 67 ± 7 years. The diagnosis of cancer preceded the diagnosis of MN in 20 ± 6.8%. Lung cancer was the most common type of tumor, accounting for 22 cases (26%), followed by prostate cancer (13 cases, 15%), hematologic malignancies (12 cases, 14%), colorectal cancer (9 cases, 11%), breast cancer (6 cases, 7%), and stomach and esophageal cancer (5 cases, 6%). Conclusion: The estimated prevalence of cancer in patients with MN is 10% (95% CI, 6.1-14.6). The vast majority of tumors associated with MN are lung and prostate cancer. Hematologic malignancies should also be considered as one of the potential cancers associated with MN. Our study was based on a largely Caucasian population; therefore, the findings might not be applicable to other populations. © 2014 S. Karger AG, Basel.en_US
dc.identifier.citationAmerican Journal of Nephrology. Vol.40, No.1 (2014), 29-35en_US
dc.identifier.doi10.1159/000364782en_US
dc.identifier.issn14219670en_US
dc.identifier.issn02508095en_US
dc.identifier.other2-s2.0-84928322079en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/123456789/34667
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84928322079&origin=inwarden_US
dc.subjectMedicineen_US
dc.titlePrevalence of cancer in membranous nephropathy: A systematic review and meta-analysis of observational studiesen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84928322079&origin=inwarden_US

Files

Collections